ATE368738T1 - Medizinische verwendung eines antikörpers oder eines antikörperfragments gegen die extrazelluläre domäne von met zur prevention von metastasen - Google Patents

Medizinische verwendung eines antikörpers oder eines antikörperfragments gegen die extrazelluläre domäne von met zur prevention von metastasen

Info

Publication number
ATE368738T1
ATE368738T1 AT97201105T AT97201105T ATE368738T1 AT E368738 T1 ATE368738 T1 AT E368738T1 AT 97201105 T AT97201105 T AT 97201105T AT 97201105 T AT97201105 T AT 97201105T AT E368738 T1 ATE368738 T1 AT E368738T1
Authority
AT
Austria
Prior art keywords
met
antibody
hgf
extracellular domain
antibody fragment
Prior art date
Application number
AT97201105T
Other languages
English (en)
Inventor
Donna L Faletto
Ilan Tsarfaty
Sing Rong
Marianne Oskarsson
Woude George F Vande
Original Assignee
Us Gov Health & Human Serv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Us Gov Health & Human Serv filed Critical Us Gov Health & Human Serv
Application granted granted Critical
Publication of ATE368738T1 publication Critical patent/ATE368738T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/4753—Hepatocyte growth factor; Scatter factor; Tumor cytotoxic factor II
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Toxicology (AREA)
  • Oncology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Compounds Of Unknown Constitution (AREA)
AT97201105T 1992-09-18 1993-09-15 Medizinische verwendung eines antikörpers oder eines antikörperfragments gegen die extrazelluläre domäne von met zur prevention von metastasen ATE368738T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US94606192A 1992-09-18 1992-09-18

Publications (1)

Publication Number Publication Date
ATE368738T1 true ATE368738T1 (de) 2007-08-15

Family

ID=25483898

Family Applications (2)

Application Number Title Priority Date Filing Date
AT93921471T ATE160585T1 (de) 1992-09-18 1993-09-15 Eine methode zur herstellung von hepatozytwachstumsfaktor und eine zelllinie
AT97201105T ATE368738T1 (de) 1992-09-18 1993-09-15 Medizinische verwendung eines antikörpers oder eines antikörperfragments gegen die extrazelluläre domäne von met zur prevention von metastasen

Family Applications Before (1)

Application Number Title Priority Date Filing Date
AT93921471T ATE160585T1 (de) 1992-09-18 1993-09-15 Eine methode zur herstellung von hepatozytwachstumsfaktor und eine zelllinie

Country Status (10)

Country Link
EP (2) EP0805203B1 (de)
JP (2) JP3553936B2 (de)
AT (2) ATE160585T1 (de)
AU (1) AU675968B2 (de)
CA (1) CA2144856A1 (de)
DE (2) DE69334159D1 (de)
DK (1) DK0662130T3 (de)
ES (1) ES2112997T3 (de)
GR (1) GR3026165T3 (de)
WO (1) WO1994006909A2 (de)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6344321B1 (en) * 1990-06-11 2002-02-05 Gilead Sciences, Inc. Nucleic acid ligands which bind to hepatocyte growth factor/scatter factor (HGF/SF) or its receptor c-met
US6566098B1 (en) 1990-09-14 2003-05-20 The United States Of America As Represented By The Department Of Health And Human Services DNA encoding truncated hepatocyte growth factor variants
CA2144081C (en) * 1992-09-16 2004-11-30 Filip Roos Protection against liver damage by hgf
US5646036A (en) * 1995-06-02 1997-07-08 Genentech, Inc. Nucleic acids encoding hepatocyte growth factor receptor antagonist antibodies
US6214344B1 (en) 1995-06-02 2001-04-10 Genetech, Inc. Hepatocyte growth factor receptor antagonists and uses thereof
US5686292A (en) 1995-06-02 1997-11-11 Genentech, Inc. Hepatocyte growth factor receptor antagonist antibodies and uses thereof
US6855685B2 (en) 1995-10-24 2005-02-15 Toshikazu Nakamura Anti-cancer agent
JP3832674B2 (ja) * 1995-10-24 2006-10-11 敏一 中村 抗癌剤
WO1998019696A1 (en) * 1996-11-05 1998-05-14 Smithkline Beecham Corporation Hepatocyte growth factor antagonists
AU1465400A (en) * 1998-11-04 2000-05-22 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The Identification of inhibitors of the hgf-met-upa-plasmin network using a novel cellular assay
IL131142A0 (en) * 1999-07-28 2001-01-28 Rad Ramot Prognosis of breast cancer and other diseases
WO2001034650A1 (en) * 1999-11-09 2001-05-17 The Government Of The United States Of America, As Represented By The Secretary, Department Of Heatlh And Human Services Hgf-sf monoclonal antibody combinations
AU2001277854B2 (en) * 2000-06-29 2007-03-01 North Shore-Long Island Jewish Health System Modulators of cellular proliferation and angiogenesis, methods for use and identification thereof
BRPI0407446A (pt) * 2003-02-13 2006-01-31 Pharmacia Corp Anticorpos para c-met para o tratamento de cânceres
TWI476206B (zh) 2003-07-18 2015-03-11 Amgen Inc 對肝細胞生長因子具專一性之結合劑
HN2004000285A (es) 2003-08-04 2006-04-27 Pfizer Prod Inc ANTICUERPOS DIRIGIDOS A c-MET
CA2575402A1 (en) 2004-08-05 2006-02-09 Genentech, Inc. Humanized anti-cmet antagonists
EP1863519B1 (de) 2005-03-31 2013-09-25 The General Hospital Corporation Modulation von hgf/hgfr-aktivität zur behandlung von lymphödem
CN101193910A (zh) 2005-04-15 2008-06-04 健泰科生物技术公司 HGFβ链变体
US8133867B2 (en) 2006-03-20 2012-03-13 Seikagaku Corporation Method for treating rheumatoid arthritis with an antibody that binds to a hepatocyte growth factor receptor
US8101727B2 (en) 2006-03-30 2012-01-24 Novartis Ag Compositions and methods of use for antibodies of c-Met
PT3904391T (pt) 2010-03-10 2024-10-14 Genmab As Anticorpos monoclonais contra c-met
RU2608644C2 (ru) 2010-11-03 2017-01-23 арДЖЕН-ИКС Н.В. Антитела против белка рецептора с-мет
AU2012240424B2 (en) 2011-04-02 2017-10-26 Washington State University Hepatocyte growth factor mimics as therapeutic agents
AR086823A1 (es) 2011-06-30 2014-01-22 Genentech Inc Formulaciones de anticuerpo anti-c-met, metodos
US9926364B2 (en) 2011-11-03 2018-03-27 Argen-X N.V. Chimeric human-llama antigens and methods of use
US9168300B2 (en) 2013-03-14 2015-10-27 Oncomed Pharmaceuticals, Inc. MET-binding agents and uses thereof
RU2016141385A (ru) 2014-03-24 2018-04-28 Дженентек, Инк. Лечение рака антагонистами с-мет и их корреляция с экспрессией hgf
ES2748295T3 (es) 2014-09-16 2020-03-16 Symphogen As Anticuerpos anti-MET y composiciones

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5648273A (en) * 1989-12-27 1997-07-15 The United States Of America, As Represented By The Department Of Health And Human Services Hepatic growth factor receptor is the MET proto-oncogene
US5362716A (en) * 1989-12-27 1994-11-08 The United States Of America As Represented By The Department Of Health And Human Services Methods for stimulating hematopoietic progenitors using hepatocyte growth factor and lymphokines
GB9003621D0 (en) * 1990-02-16 1990-04-11 Imp Cancer Res Tech Protein factor
JP2784455B2 (ja) * 1990-05-09 1998-08-06 敏一 中村 肝硬変治療剤
EP0571387B1 (de) * 1990-09-14 2003-12-17 THE UNITED STATES OF AMERICA as represented by the Secretary United States Department of Commerce Ein nicht-mitogener kompetitiver hgf-antagonist
ATE222603T1 (de) * 1992-05-18 2002-09-15 Genentech Inc Hepatozytwachstumfaktor variante

Also Published As

Publication number Publication date
JPH08504093A (ja) 1996-05-07
EP0662130B1 (de) 1997-11-26
ES2112997T3 (es) 1998-04-16
DK0662130T3 (da) 1998-08-10
WO1994006909A2 (en) 1994-03-31
DE69315440T2 (de) 1998-07-09
JP3553936B2 (ja) 2004-08-11
JP2004002440A (ja) 2004-01-08
CA2144856A1 (en) 1994-03-31
EP0805203B1 (de) 2007-08-01
WO1994006909A3 (en) 1994-05-26
DE69334159D1 (de) 2007-09-13
AU675968B2 (en) 1997-02-27
DE69315440D1 (de) 1998-01-08
EP0662130A1 (de) 1995-07-12
AU4855593A (en) 1994-04-12
ATE160585T1 (de) 1997-12-15
GR3026165T3 (en) 1998-05-29
EP0805203A1 (de) 1997-11-05

Similar Documents

Publication Publication Date Title
ATE368738T1 (de) Medizinische verwendung eines antikörpers oder eines antikörperfragments gegen die extrazelluläre domäne von met zur prevention von metastasen
DK1294769T3 (da) Antistoffer der immunspecifikt binder til BLyS
DE69433406D1 (de) Antikörper gegen cd40
UA111707C2 (uk) Застосування виділеного анти-tnf-альфа антитіла людини
BG101024A (bg) Моноклонално антитяло срещу сd44v6
BRPI0413489A (pt) composições polipeptìdicas de ligação a cd20
DK0536275T3 (da) Tumorvækstinhibitorer udledt fra væv, fremgangsmåde til deres fremstilling samt anvendelse heraf
DE68927671D1 (de) Produkte zur Behandlung des Endotoxin -Schocks bei einem Säugetier
ATE236271T1 (de) Verwendung der ndv zur herstellung eines medikaments zur krebsbehandlung
DE69002325D1 (de) Pharmazeutische zusammensetzung zur verhuetung oder heilung von durch den papillomavirus induzierten tumoren.
ATE330631T1 (de) Antikörperfragmente zur lokalen behandlung von augenerkrankungen
DE69112717D1 (de) Neue Verwendung von Modafinil.
BR9707819A (pt) Imunogenos peptidicos
ATE194168T1 (de) Varianten in den leltin domäne von selektin
BR0314369A (pt) Métodos para inibir o crescimento de uma célula, para induzir morte celular de uma célula de câncer, para tratar ou prevenir câncer em um indivìduo e para identificar um agente que inibe o crescimento canceroso de uma célula, agente, e, anticorpo ephb4 purificado
DE69211899D1 (de) Siloxan modifizierter Polyester zur Behandlung von Fasern
DE60238987D1 (de) Behandlung von bauchspeicheldrüsenkrebs mit einem monoklonalen antikörper
ATE173620T1 (de) Verwendung eines antagonisten von tnf-alpha zur behandlung von hautrötungen neurogenen ursprungs
DE69006221D1 (de) Verfahren zur behandlung von septischem schock.
GR76280B (de)
NO955172L (no) Delesjonsvarianter av protein S med manglende C4BP-bindingsaktivitet, men med APC-kofaktoraktivitet, samt materiale og terapeutiske metoder
EA199800821A1 (ru) Способ лечения аутизма
DE69408394D1 (de) 4-Piperidino-piperidin zur Behandlung von Tumoren
FR2658204B1 (de)
ATE291434T1 (de) Verwendung von angiotensin zur behandlung von krebsmetastasierung

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties